{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:01:12Z","timestamp":1794013272814,"version":"4.8.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Evaluation project on national immunization program of China"},{"name":"Shanghai New Three-year Action Plan for Public Health","award":["GWV-10.1-XK16"],"award-info":[{"award-number":["GWV-10.1-XK16"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Poverty"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Elimination of hepatitis B virus (HBV) is a striking challenge for countries with high or moderate disease burden. Therefore, using China as a practical case to share experiences for similar countries may accelerate the achievement of the WHO 2030 target of 90% reduction in HBV-related incidence. We aim to evaluate the impact of national HBV immunization strategies in China; and the feasibility to achieve WHO 2030 targets under different scenarios.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We constructed an expanded Susceptible-Exposed-Infectious-Recovered (SEIR) model and decision tree-Markov model to estimate the epidemic of HBV in China, assess the feasibility of 2030 Elimination Goals through the projections and conduct the economic analysis. Least square method was used to calibrate the expanded SEIR model by yearly data of laboratory-confirmed HBV cases from 1990 to 2018. Two models were separately used to evaluate the impact and cost-effectiveness of HBV vaccine by comparing prevalence of chronic HBV infections, quality-adjusted life-years (QALYs), incremental cost effectiveness ratio and benefit\u2013cost ratio (BCR) under various intervention options, providing a basis for exploring new containment strategies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between 1990 and 2020, the number of chronic HBV infections decreased by 33.9%. The current status quo would lead to 55.73 million infections (3.95% prevalence) in 2030, compared to 90.63 million (6.42% prevalence) of the \u201cWithout the NIP\u201d scenario (NIP: National Immunization Program), 114.78 million (8.13% prevalence) without any interventions. The prevention of mother to child transmission (PMTCT) strategy showed a net benefit as 12,283.50 dollars per person, with BCR as 12.66, which is higher than that of universal vaccination at 9.49. Compared with no screening and no vaccination, the PMTCT strategy could save 7726.03 dollars for each QALY increase.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings proved the HBV vaccination has demonstrated a substantial positive impact on controlling the epidemic of HBV in terms of effectiveness and economy after about 30\u00a0years of implementation of the national hepatitis B immunization program which also provided containment experience for high or medium burden countries. As for China, the next step should focus on exploring strategies to improve diagnosis and treatment coverage to reduce the burden of HBV-related deaths and ultimately eliminate HBV.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40249-022-01032-5","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T10:03:11Z","timestamp":1665482591000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Impact of the national hepatitis B immunization program in China: a modeling study"],"prefix":"10.1186","volume":"11","author":[{"given":"Zhixi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abram L.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingsheng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4497-5251","authenticated-orcid":false,"given":"Weibing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"key":"1032_CR1","unstructured":"Global Burden of Disease Liver Cancer C, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3(12):1683\u201391."},{"issue":"3","key":"1032_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","volume":"5","author":"GBDC Collaborators","year":"2020","unstructured":"Collaborators GBDC. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(3):245\u201366.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1032_CR3","unstructured":"WHO. Hepatitis B: Key facts. world Health Organization https:\/\/www.whoint\/news-room\/fact-sheets\/detail\/hepatitis-b. Accessed 28 Aug 2022."},{"key":"1032_CR4","unstructured":"WHO. Summary of WHO Position Paper on Hepatitis B Vaccines. World Health Organization. 2017."},{"issue":"9","key":"1032_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41575-020-0332-6","volume":"17","author":"AL Cox","year":"2020","unstructured":"Cox AL, El-Sayed MH, Kao JH, Lazarus JV, Lemoine M, Lok AS, et al. Progress towards elimination goals for viral hepatitis. Nat Rev Gastroenterol Hepatol. 2020;17(9):533\u201342.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"1032_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S2468-1253(18)30270-X","volume":"4","author":"GS Cooke","year":"2019","unstructured":"Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology and Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4(2):135\u201384.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"1032_CR7","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1473-3099(16)30204-3","volume":"16","author":"S Nayagam","year":"2016","unstructured":"Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16(12):1399\u2013408.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"1032_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jhepr.2019.04.002","volume":"1","author":"S Smith","year":"2019","unstructured":"Smith S, Harmanci H, Hutin Y, Hess S, Bulterys M, Peck R, et al. Global progress on the elimination of viral hepatitis as a major public health threat: an analysis of WHO Member State responses 2017. JHEP Rep Innov Hepatol. 2019;1(2):81\u20139.","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"3","key":"1032_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2471\/BLT.18.219469","volume":"97","author":"J Liu","year":"2019","unstructured":"Liu J, Liang W, Jing W, Liu M. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ. 2019;97(3):230\u20138.","journal-title":"Bull World Health Organ"},{"key":"1032_CR10","unstructured":"WHO. Global health sector strategy on viral hepatitis, 2016\u20132021\u2014towards ending hepatitis. World Health Organization https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/246177\/WHO-HIV-201606-engpdf;jsessionid=C218A471F69D97C680E0940470EB5455?sequence=1. Accessed Dec 22, 2020."},{"key":"1032_CR11","unstructured":"World Health Organization. Global hepatitis report 2017. https:\/\/apps.who.int\/iris\/bitstream\/10665\/255016\/1\/9789241565455-eng.pdf?ua=1 . Accessed June 20."},{"issue":"3","key":"1032_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/COH.0000000000000617","volume":"15","author":"M Toy","year":"2020","unstructured":"Toy M, So S, Hutton DW. Hepatitis B cure: modeling the economics of a potential cost of a cure. Curr Opin HIV AIDS. 2020;15(3):208\u201312.","journal-title":"Curr Opin HIV AIDS"},{"issue":"12","key":"1032_CR13","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1016\/j.vaccine.2011.01.025","volume":"29","author":"Q Wu","year":"2011","unstructured":"Wu Q, Zhuang GH, Wang XL, Wang LR, Li N, Zhang M. Antibody levels and immune memory 23 years after primary plasma-derived hepatitis B vaccination: results of a randomized placebo-controlled trial cohort from China where endemicity is high. Vaccine. 2011;29(12):2302\u20137.","journal-title":"Vaccine"},{"issue":"10003","key":"1032_CR14","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet (London, England). 2015;386(10003):1546\u201355.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"1032_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/S1473-3099(15)00218-2","volume":"16","author":"J Liu","year":"2016","unstructured":"Liu J, Zhang S, Wang Q, Shen H, Zhang M, Zhang Y, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21\u201349 years in rural China: a population-based, cross-sectional study. Lancet Infect Dis. 2016;16(1):80\u20136.","journal-title":"Lancet Infect Dis"},{"key":"1032_CR16","unstructured":"WHO. Up to 10 million people in China could die from chronic hepatitis by 2030\u2014Urgent action needed to bring an end to the \u2018silent epidemic\u2019. World Health Organization https:\/\/www.whoint\/china\/news\/detail\/26-07-2016-up-to-10-million-people-in-china-could-die-from-chronic-hepatitis-by-2030-urgent-action-needed-to-bring-an-end-to-the-silent-epidemic . Accessed Dec 22, 2020."},{"issue":"Suppl 9","key":"1032_CR17","doi-asserted-by":"publisher","first-page":"J21","DOI":"10.1016\/j.vaccine.2013.08.012","volume":"31","author":"X Liang","year":"2013","unstructured":"Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Reprint of: Epidemiological serosurvey of Hepatitis B in China\u2014declining HBV prevalence due to Hepatitis B vaccination. Vaccine. 2013;31(Suppl 9):J21\u20138.","journal-title":"Vaccine"},{"issue":"1","key":"1032_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1086\/599332","volume":"200","author":"X Liang","year":"2009","unstructured":"Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Evaluation of the impact of Hepatitis B vaccination among children born during 1992\u20132005 in China. J Infect Dis. 2009;200(1):39\u201347.","journal-title":"J Infect Dis"},{"key":"1032_CR19","unstructured":"Zhang S, Ma Q, Liang S, Xiao H, Zhuang G, Zou Y, et al. Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China. (1365\u20132893 (Electronic))."},{"issue":"5","key":"1032_CR20","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.4161\/hv.23827","volume":"9","author":"S Boccalini","year":"2013","unstructured":"Boccalini S, Taddei C, Ceccherini V, Bechini A, Levi M, Bartolozzi D, et al. Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy: an a posteriori evaluation and forecast of future benefits. Hum Vaccin Immunother. 2013;9(5):1119\u201328.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"1032_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.vhri.2012.03.007","volume":"1","author":"HAT Tu","year":"2012","unstructured":"Tu HAT, de Vries R, Woerdenbag HJ, Li SC, Le HH, van Hulst M, et al. Cost-effectiveness analysis of hepatitis B immunization in Vietnam: application of cost-effectiveness affordability curves in health care decision making. Value Health Reg Issues. 2012;1(1):7\u201314.","journal-title":"Value Health Reg Issues"},{"issue":"6","key":"1032_CR22","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1080\/21645515.2020.1845522","volume":"17","author":"AM Mokhtari","year":"2021","unstructured":"Mokhtari AM, Barouni M, Moghadami M, Hassanzadeh J, Dewey RS, Mirahmadizadeh A. Evaluating the cost-effectiveness of universal hepatitis B virus vaccination in Iran: a Markov model analysis. Hum Vaccin Immunother. 2021;17(6):1825\u201333.","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"1032_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003068","volume":"17","author":"AL McNaughton","year":"2020","unstructured":"McNaughton AL, Lourenco J, Bester PA, Mokaya J, Lumley SF, Obolski U, et al. Hepatitis B virus seroepidemiology data for Africa: modelling intervention strategies based on a systematic review and meta-analysis. PLoS Med. 2020;17(4): e1003068.","journal-title":"PLoS Med"},{"key":"1032_CR24","unstructured":"WHO. Global Health Observatory data repository: maternal and reproductive health. https:\/\/apps.who.int\/gho\/data\/view.main.1610?lang=en . Accessed June 20."},{"key":"1032_CR25","unstructured":"WHO. Hepatitis B vaccination: an updated systematic review of economic evaluation in low and middle income countries. World Health Organization https:\/\/www.whoint\/immunization\/sage\/meetings\/2016\/october\/8_Hep_B_economic_evaluation_LMICpdf?ua=1. Accessed Dec 22, 2020."},{"issue":"7","key":"1032_CR26","doi-asserted-by":"publisher","first-page":"e931","DOI":"10.1016\/S2214-109X(20)30231-X","volume":"8","author":"CP Seaman","year":"2020","unstructured":"Seaman CP, Morgan C, Howell J, Xiao Y, Spearman CW, Sonderup M, et al. Use of controlled temperature chain and compact prefilled auto-disable devices to reach 2030 hepatitis B birth dose vaccination targets in LMICs: a modelling and cost-optimisation study. Lancet Glob Health. 2020;8(7):e931\u201341.","journal-title":"Lancet Glob Health"},{"key":"1032_CR27","doi-asserted-by":"crossref","unstructured":"Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383\u2013403.","DOI":"10.1016\/S2468-1253(18)30056-6"},{"key":"1032_CR28","unstructured":"WHO. Progress report on HIV, viral hepatitis and sexually transmitted infections 2019. Accountability for the global health sector strategies, 2016\u20132021. WOrld Health Organization https:\/\/www.whoint\/hiv\/strategy2016-2021\/progress-report-2019\/en\/. Accessed Dec 22, 2020."},{"issue":"5","key":"1032_CR29","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/jvh.12839","volume":"25","author":"Y Chen","year":"2018","unstructured":"Chen Y, Xie C, Zhang Y, Li Y, Ehrhardt S, Thio CL, et al. Knowledge regarding hepatitis B mother-to-child transmission among healthcare workers in South China. J Viral Hepatitis. 2018;25(5):561\u201370.","journal-title":"J Viral Hepatitis"},{"issue":"Suppl 1","key":"1032_CR30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/liv.13640","volume":"38","author":"M Subic","year":"2018","unstructured":"Subic M, Zoulim F. How to improve access to therapy in hepatitis B patients. Liver Int. 2018;38(Suppl 1):115\u201321.","journal-title":"Liver Int"},{"issue":"1","key":"1032_CR31","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1186\/s12879-019-4428-y","volume":"19","author":"H Wang","year":"2019","unstructured":"Wang H, Men P, Xiao Y, Gao P, Lv M, Yuan Q, et al. Hepatitis B infection in the general population of China: a systematic review and meta-analysis. BMC Infect Dis. 2019;19(1):811.","journal-title":"BMC Infect Dis"},{"issue":"12","key":"1032_CR32","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1136\/gutjnl-2015-309892","volume":"65","author":"Y Shimakawa","year":"2016","unstructured":"Shimakawa Y, Lemoine M, Njai HF, Bottomley C, Ndow G, Goldin RD, et al. Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia. Gut. 2016;65(12):2007\u201316.","journal-title":"Gut"},{"issue":"8","key":"1032_CR33","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/oxfordjournals.aje.a117321","volume":"140","author":"SA Marion","year":"1994","unstructured":"Marion SA, Tomm Pastore M, Pi DW, Mathias RG. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol. 1994;140(8):734\u201346.","journal-title":"Am J Epidemiol"}],"container-title":["Infectious Diseases of Poverty"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-022-01032-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40249-022-01032-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-022-01032-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T22:05:24Z","timestamp":1665525924000},"score":1,"resource":{"primary":{"URL":"https:\/\/idpjournal.biomedcentral.com\/articles\/10.1186\/s40249-022-01032-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1032"],"URL":"https:\/\/doi.org\/10.1186\/s40249-022-01032-5","relation":{},"ISSN":["2049-9957"],"issn-type":[{"value":"2049-9957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]},"assertion":[{"value":"15 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have declared: no support from any organizations for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}